CUSIP No. 45332Y109
||Page 8 of 10 Pages
Item 4. Purpose of Transaction.
Item 4 of the Schedule 13D is hereby amended and supplemented by
adding the following:
Between August 27, 2021 and September 7, 2021, Gilde
Healthcare sold an aggregate of 848,145 shares of Common Stock of
the Issuer in open market transactions as set forth on Annex
A to this Schedule 13D.
Item 5. Interest in Securities of the Issuer.
Item 5 is hereby amended and restated in its entirety below:
(a) According to the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission (“SEC”) on August 10, 2021, there were
49,928,519 shares of Common Stock outstanding as of August 6,
Gilde Healthcare is the record holder of an aggregate of 2,400,612
shares of Common Stock, which represents beneficial ownership of
approximately 4.8% of the outstanding shares of Common Stock
reported as of August 6, 2021.
GHCIVM, as the manager of Gilde Healthcare, has the power to vote
and dispose of securities held by Gilde Healthcare and may be
deemed to beneficially own the securities held of record by Gilde
As a result, each of the Reporting Persons may beneficially own an
aggregate of 2,400,612 shares of Common Stock, or approximately
4.8% of the outstanding Common Stock.
(b) Each Reporting Person has shared power to vote and dispose of
2,400,612 shares of Common Stock.
(c) Except as reported on Annex A, none of the
Reporting Persons has effected any transactions in the Issuer’s
securities within the past 60 days.
(d) Only Gilde Healthcare has the right to receive dividends
from, or the proceeds from, the sale of shares of the Issuer owned
by Gilde Healthcare.
(e) As a result of the sales described herein, the Reporting
Persons ceased to be the beneficial owner of more than 5% of the
Issuer’s Common Stock. The filing of this Amendment No. 6
represents the final amendment to this Schedule 13D and constitutes
an exit filing for the Reporting Persons.
Item 6. Contracts, Arrangements, Understandings or
Relationships with Respect to the Securities of the Issuer.
Except as referenced herein, there are no changes to the Item 6
information previously filed.